HeimNSIS-B • CPH
add
Novozymes
Við síðustu lokun
400,90 kr.
Dagbil
398,90 kr. - 403,30 kr.
Árabil
375,90 kr. - 485,90 kr.
Markaðsvirði
166,98 ma. DKK
Meðalmagn
486,99 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
CPH
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 915,85 m. | 61,70% |
Rekstrarkostnaður | 271,75 m. | 52,62% |
Nettótekjur | 31,95 m. | -60,72% |
Hagnaðarhlutfall | 3,49 | -75,70% |
Hagnaður á hvern hlut | — | — |
EBITDA | 150,94 m. | -16,50% |
Virkt skatthlutfall | 29,00% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 260,80 m. | 85,35% |
Heildareignir | 15,25 ma. | 302,43% |
Heildarskuldir | 4,25 ma. | 119,23% |
Eigið fé alls | 11,00 ma. | — |
Útistandandi hlutabréf | 277,90 m. | — |
Eiginfjárgengi | 10,12 | — |
Arðsemi eigna | 1,83% | — |
Ávöxtun eigin fjár | 2,15% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 31,95 m. | -60,72% |
Handbært fé frá rekstri | 264,05 m. | 74,01% |
Reiðufé frá fjárfestingum | -27,45 m. | 70,98% |
Reiðufé frá fjármögnun | -186,70 m. | -205,10% |
Breyting á handbæru fé | 55,55 m. | 902,56% |
Frjálst peningaflæði | -17,57 m. | 68,87% |
Um
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. Wikipedia
Framkvæmdastjóri
Stofnsett
2000
Vefsvæði
Starfsfólk
10.452
